Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Modeling the effect of collagen fibril alignment on ligament mechanical behavior.

Stender CJ, Rust E, Martin PT, Neumann EE, Brown RJ, Lujan TJ.

Biomech Model Mechanobiol. 2018 Apr;17(2):543-557. doi: 10.1007/s10237-017-0977-4. Epub 2017 Nov 24.

PMID:
29177933
2.

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.

Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT.

Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):91-101. doi: 10.1007/s13318-017-0429-7.

3.

Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.

Cramer ML, Shao G, Rodino-Klapac LR, Chicoine LG, Martin PT.

Hum Gene Ther. 2017 Jun;28(6):493-509. doi: 10.1089/hum.2016.113. Epub 2017 Mar 23.

4.

Deletion of Pofut1 in Mouse Skeletal Myofibers Induces Muscle Aging-Related Phenotypes in cis and in trans.

Zygmunt DA, Singhal N, Kim ML, Cramer ML, Crowe KE, Xu R, Jia Y, Adair J, Martinez-Pena Y Valenzuela I, Akaaboune M, White P, Janssen PM, Martin PT.

Mol Cell Biol. 2017 May 2;37(10). pii: e00426-16. doi: 10.1128/MCB.00426-16. Print 2017 May 15.

5.

Loss of CMAH during Human Evolution Primed the Monocyte-Macrophage Lineage toward a More Inflammatory and Phagocytic State.

Okerblom JJ, Schwarz F, Olson J, Fletes W, Ali SR, Martin PT, Glass CK, Nizet V, Varki A.

J Immunol. 2017 Mar 15;198(6):2366-2373. doi: 10.4049/jimmunol.1601471. Epub 2017 Feb 1.

6.

Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Zygmunt DA, Crowe KE, Flanigan KM, Martin PT.

Hum Gene Ther. 2017 Sep;28(9):737-746. doi: 10.1089/hum.2016.141. Epub 2016 Dec 29.

PMID:
28042944
7.

N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.

Crowe KE, Shao G, Flanigan KM, Martin PT.

J Neuromuscul Dis. 2016 May 27;3(2):247-260.

9.

B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Thomas PJ, Xu R, Martin PT.

Am J Pathol. 2016 Sep;186(9):2429-48. doi: 10.1016/j.ajpath.2016.05.021.

10.

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.

Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin PT.

Ther Drug Monit. 2016 Aug;38(4):546-55. doi: 10.1097/FTD.0000000000000296.

11.

Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Xu R, Singhal N, Serinagaoglu Y, Chandrasekharan K, Joshi M, Bauer JA, Janssen PM, Martin PT.

Am J Pathol. 2015 Oct;185(10):2668-84. doi: 10.1016/j.ajpath.2015.06.008.

12.

A role for Galgt1 in skeletal muscle regeneration.

Singhal N, Martin PT.

Skelet Muscle. 2015 Jan 27;5:3. doi: 10.1186/s13395-014-0028-0. eCollection 2015.

13.

A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.

Martin PT, Golden B, Okerblom J, Camboni M, Chandrasekharan K, Xu R, Varki A, Flanigan KM, Kornegay JN.

PLoS One. 2014 Feb 5;9(2):e88226. doi: 10.1371/journal.pone.0088226. eCollection 2014.

15.

Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, Heller KN, Lewis S, Malik V, Grose WE, Shilling CJ, Campbell KJ, Preston TJ, Coley BD, Martin PT, Walker CM, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR.

Mol Ther. 2014 Feb;22(2):338-347. doi: 10.1038/mt.2013.244. Epub 2013 Oct 23.

16.

Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.

Chicoine LG, Rodino-Klapac LR, Shao G, Xu R, Bremer WG, Camboni M, Golden B, Montgomery CL, Shontz K, Heller KN, Griffin DA, Lewis S, Coley BD, Walker CM, Clark KR, Sahenk Z, Mendell JR, Martin PT.

Mol Ther. 2014 Apr;22(4):713-24. doi: 10.1038/mt.2013.246. Epub 2013 Oct 22.

17.

Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.

Camboni M, Wang CM, Miranda C, Yoon JH, Xu R, Zygmunt D, Kaspar BK, Martin PT.

Neurobiol Dis. 2014 Feb;62:31-43. doi: 10.1016/j.nbd.2013.09.001. Epub 2013 Sep 8.

18.

Identification of new dystroglycan complexes in skeletal muscle.

Johnson EK, Li B, Yoon JH, Flanigan KM, Martin PT, Ervasti J, Montanaro F.

PLoS One. 2013 Aug 8;8(8):e73224. doi: 10.1371/journal.pone.0073224. eCollection 2013.

19.

N-Glycolylneuraminic acid deficiency worsens cardiac and skeletal muscle pathophysiology in α-sarcoglycan-deficient mice.

Martin PT, Camboni M, Xu R, Golden B, Chandrasekharan K, Wang CM, Varki A, Janssen PM.

Glycobiology. 2013 Jul;23(7):833-43. doi: 10.1093/glycob/cwt020. Epub 2013 Mar 20.

20.

Distinct contributions of Galgt1 and Galgt2 to carbohydrate expression and function at the mouse neuromuscular junction.

Singhal N, Xu R, Martin PT.

Mol Cell Neurosci. 2012 Nov;51(3-4):112-26. doi: 10.1016/j.mcn.2012.08.014. Epub 2012 Sep 7.

21.

Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Yoon JH, Johnson E, Xu R, Martin LT, Martin PT, Montanaro F.

J Proteome Res. 2012 Sep 7;11(9):4413-24. doi: 10.1021/pr300328r. Epub 2012 Jul 30.

22.

Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration.

Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, Lee J, Peter AK, Martin PT, Crosbie-Watson RH.

J Cell Biol. 2012 Jun 25;197(7):1009-27. doi: 10.1083/jcb.201110032.

23.

A lethal injection?

Arumugam D, Atherton JJ, Martin PT.

Lancet. 2012 Feb 4;379(9814):492. doi: 10.1016/S0140-6736(11)61711-X. No abstract available.

PMID:
22305227
24.

Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice.

Camboni M, Hammond S, Martin LT, Martin PT.

J Pathol. 2012 Jan;226(1):40-9. doi: 10.1002/path.2996. Epub 2011 Oct 18.

25.

Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction.

Singhal N, Martin PT.

Dev Neurobiol. 2011 Nov;71(11):982-1005. doi: 10.1002/dneu.20953. Review.

26.

The carbohydrate CT1 is expressed in topographically fixed glomeruli in the mouse olfactory bulb.

Lineburg KE, Amaya D, Ekberg JA, Chehrehasa F, Mackay-Sim A, Martin PT, Key B, St John JA.

Mol Cell Neurosci. 2011 Sep;48(1):9-19. doi: 10.1016/j.mcn.2011.05.011. Epub 2011 Jun 12.

PMID:
21699983
27.

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

Ermer JC, Dennis K, Haffey MB, Doll WJ, Sandefer EP, Buckwalter M, Page RC, Diehl B, Martin PT.

Clin Drug Investig. 2011;31(6):357-70. doi: 10.2165/11588190-000000000-00000.

PMID:
21539403
28.

Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.

McCarty DM, DiRosario J, Gulaid K, Killedar S, Oosterhof A, van Kuppevelt TH, Martin PT, Fu H.

Metab Brain Dis. 2011 Mar;26(1):9-19. doi: 10.1007/s11011-010-9230-x. Epub 2011 Jan 12.

29.

Genetic defects in muscular dystrophy.

Chandrasekharan K, Martin PT.

Methods Enzymol. 2010;479:291-322. doi: 10.1016/S0076-6879(10)79017-0. Review.

PMID:
20816173
30.

A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy.

Chandrasekharan K, Yoon JH, Xu Y, deVries S, Camboni M, Janssen PM, Varki A, Martin PT.

Sci Transl Med. 2010 Jul 28;2(42):42ra54. doi: 10.1126/scitranslmed.3000692.

31.

Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.

Wang CM, Devries S, Camboni M, Glass M, Martin PT.

Neurobiol Dis. 2010 Sep;39(3):409-22. doi: 10.1016/j.nbd.2010.05.013. Epub 2010 May 20.

32.

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Fernandez K, Serinagaoglu Y, Hammond S, Martin LT, Martin PT.

Am J Pathol. 2010 Jan;176(1):416-34. doi: 10.2353/ajpath.2010.090405. Epub 2009 Dec 17.

33.

An investigation of driver distraction near the tipping point of traffic flow stability.

Cooper JM, Vladisavljevic I, Medeiros-Ward N, Martin PT, Strayer DL.

Hum Factors. 2009 Apr;51(2):261-8.

PMID:
19653488
34.

Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.

Xu R, DeVries S, Camboni M, Martin PT.

Am J Pathol. 2009 Jul;175(1):235-47. doi: 10.2353/ajpath.2009.080967. Epub 2009 Jun 4.

35.

The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Yoon JH, Chandrasekharan K, Xu R, Glass M, Singhal N, Martin PT.

Mol Cell Neurosci. 2009 Aug;41(4):448-63. doi: 10.1016/j.mcn.2009.04.013. Epub 2009 May 12.

36.

Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice.

Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, Montgomery CL, Shontz K, Chicoine LG, Clark KR, Sahenk Z, Mendell JR, Janssen PM.

Am J Physiol Cell Physiol. 2009 Mar;296(3):C476-88. doi: 10.1152/ajpcell.00456.2008. Epub 2008 Dec 24.

37.

Embryonic overexpression of Galgt2 inhibits skeletal muscle growth via activation of myostatin signaling.

Chandraskeharan K, Martin PT.

Muscle Nerve. 2009 Jan;39(1):25-41. doi: 10.1002/mus.21198.

PMID:
19086062
38.

Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Martin PT, Shelton GD, Dickinson PJ, Sturges BK, Xu R, LeCouteur RA, Guo LT, Grahn RA, Lo HP, North KN, Malik R, Engvall E, Lyons LA.

Neuromuscul Disord. 2008 Dec;18(12):942-52. doi: 10.1016/j.nmd.2008.08.002. Epub 2008 Nov 5.

39.

O-fucosylation of muscle agrin determines its ability to cluster acetylcholine receptors.

Kim ML, Chandrasekharan K, Glass M, Shi S, Stahl MC, Kaspar B, Stanley P, Martin PT.

Mol Cell Neurosci. 2008 Nov;39(3):452-64. doi: 10.1016/j.mcn.2008.07.026. Epub 2008 Aug 15.

40.

Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors.

Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4318-22. doi: 10.1073/pnas.0709144105. Epub 2008 Mar 11.

41.

Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors.

Martin LT, Glass M, Dosunmu E, Martin PT.

Hum Pathol. 2007 Nov;38(11):1657-68. Epub 2007 Jul 19.

42.
43.

Congenital muscular dystrophies involving the O-mannose pathway.

Martin PT.

Curr Mol Med. 2007 Jun;7(4):417-25. Review.

45.

The congenital muscular dystrophies: recent advances and molecular insights.

Mendell JR, Boué DR, Martin PT.

Pediatr Dev Pathol. 2006 Nov-Dec;9(6):427-43. Review.

46.
47.

Benefit of millisecond waveform durations for patients with high defibrillation thresholds.

Denman RA, Umesan C, Martin PT, Forbes RN, Kroll MW, Anskey EJ, Burnett HE.

Heart Rhythm. 2006 May;3(5):536-41. Epub 2006 Feb 28.

PMID:
16648057
48.

The dystroglycanopathies: the new disorders of O-linked glycosylation.

Martin PT.

Semin Pediatr Neurol. 2005 Sep;12(3):152-8. Review.

49.

Effectiveness of traffic management in Salt Lake City, Utah.

Cottrell WD, Kim N, Martin PT, Perrin HJ Jr.

J Safety Res. 2006;37(1):27-41. Epub 2006 Mar 3.

PMID:
16516928
50.

Glycobiology of the neuromuscular junction.

Martin PT.

J Neurocytol. 2003 Jun-Sep;32(5-8):915-29. Review.

PMID:
15034276

Supplemental Content

Loading ...
Support Center